PETER RICHARDSON to Antiviral Agents
This is a "connection" page, showing publications PETER RICHARDSON has written about Antiviral Agents.
Connection Strength
0.939
-
Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct-Acting Antivirals Versus Interferon. Aliment Pharmacol Ther. 2025 04; 61(7):1226-1237.
Score: 0.594
-
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci Adv. 2021 01; 7(1).
Score: 0.112
-
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med. 2020 08 07; 12(8):e12697.
Score: 0.108
-
Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol. 2011 Mar; 106(3):483-91.
Score: 0.055
-
The Risk of Hepatocellular Carcinoma in Entecavir Versus Tenofovir Treated US Cohort With Chronic Hepatitis B Virus. Clin Gastroenterol Hepatol. 2023 04; 21(4):1111-1113.e3.
Score: 0.030
-
Hepatocellular carcinoma screening practices in the Department of Veterans Affairs: findings from a national facility survey. Dig Dis Sci. 2013 Nov; 58(11):3117-26.
Score: 0.017
-
Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol. 2012 Feb; 56(2):320-5.
Score: 0.014
-
Survival in hepatitis C and HIV co-infection: a cohort study of hospitalized veterans. Clin Gastroenterol Hepatol. 2005 Feb; 3(2):175-83.
Score: 0.009